Trial Profile
A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine on Top of OADs in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LixiLan JP-O2
- Sponsors Sanofi
- 01 Dec 2021 Results of post-hoc analysis compare the benefits of iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi), with insulin glargine (iGlar) for reducing residual hyperglycaemia in Japanese people with type 2 diabetes published in the Diabetes, Obesity and Metabolism
- 26 Mar 2018 Status changed from active, no longer recruiting to completed.
- 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.